WHO ICTRP trial
Prospective Phase ll trial of Erlotinib for Advanced Non Small Cell Lung Cancer…
JPRN-UMIN000002880 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-UMIN000002880 |
|---|---|
| Public title | Prospective Phase ll trial of Erlotinib for Advanced Non Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations |
| Scientific title | Prospective Phase ll trial of Erlotinib for Advanced Non Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations - Prospective Phase ll trial of Erlotinib for Advanced Non Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations |
| Primary sponsor | Federation of National Public Service Personnel Mutual Aid Associations TORANOMON HOSPITAL Department of Respiratory Medicine |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase II |
| Countries | Japan |
| Conditions | Non-small cell Lung Cancer |
| Interventions | Erlotinib 150mg daily |
| Registration date | Nov 12, 2009 |
| Target size | 30 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: